Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results

We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corcept Therapeutics Inc. was one of the best performers on Thursday.

Corcept Therapeutics extended its winning streak to a third consecutive day on Thursday, jumping 13.74 percent to close at $41.30 apiece as investors cheered clinical results from its late-stage study of drug candidate, relacorilant, in patients with platinum-resistant ovarian cancer.

In an updated report, Corcept Therapeutics Inc. said that relacorilant, when combined with nab-paclitaxel chemotherapy, showed a 35 percent reduction of death risks in patients, as compared with those treated with nab-paclitaxel alone, during the third phase of its clinical trial. The therapy was also able to cut disease progression by 30 percent.

Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results

The median overall survival for patients receiving relacorilant was 16 months, as compared with 11.9 months for those receiving nab-paclitaxel alone.

Corcept Therapeutics Inc. said that relacorilant, in combination with nab-paclitaxel, was well-tolerated, consistent with its known safety profile.

The trial enrolled a total of 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel, or nab-paclitaxel alone.

Corcept Therapeutics Inc. said that complete results from the study are set to be announced at an upcoming medical conference.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.